GuidelineJournal of the European Academy of Dermatology and Venereology : JEADV2025
European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment.
Guideline in Journal of the European Academy of Dermatology and Venereology : JEADV, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Modalities of Combined Medical and Surgical Treatment in Hidradenitis Suppurativa: A Systematic Review of Efficacy and Safety.Dermatology and therapy · 2026Pooled it
- Short-term efficacy of biologics in moderate-to-severe hidradenitis suppurativa: A systematic review and NMA.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Pooled it
- Dietary patterns, metabolic pathways and metainflammation in hidradenitis suppurativa: a systematic review.Frontiers in immunology · 2026Pooled it
- Systematic review of laser and Light-Based procedural treatments for hidradenitis suppurativa.Lasers in medical science · 2025Pooled it
- European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Guideline
- Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials.Nature medicine · 2026Trial
- Treatment trajectories and patterns following non-medical switching to biosimilar adalimumab in patients with hidradenitis suppurativa: a retrospective observational multicenter study from Saudi Arabia.Future science OA · 2026Article
- 'My HS is significantly impacted by my cycle': a cross-sectional study exploring the impact of menstruation and pregnancy on hidradenitis suppurativa.Skin health and disease · 2026Article
- Real-World Effectiveness and Safety of Bimekizumab for Moderate-to-Severe Hidradenitis Suppurativa: A Multicenter Retrospective Study from the Italian Landscape HS (IL-HS).Dermatology and therapy · 2026Article
- Position Statement of the EADV Task Forces With External Experts on Quality of Life Measurement in Hidradenitis Suppurativa: An Update.International journal of dermatology · 2026Review
- The Expanding Role of GLP-1 Receptor Agonists and Dual GIP/GLP-1 Agonists in Dermatology: From Immunometabolism to Clinical Practice.Dermatology and therapy · 2026Review
- Window of Opportunity and Predictors of Sustained Remission in Patients with Hidradenitis Suppurativa Treated with Adalimumab: A 540-Patient Cohort Study.Dermatology and therapy · 2026Article
- Hidradenitis Suppurativa from Preconception to Lactation: Clinical Treatment Decision-Making Review.Dermatology and therapy · 2026Review
- Oral Zinc Supplementation in Acne Vulgaris and Hidradenitis Suppurativa: An Updated Comprehensive Review.Nutrients · 2026Review
- Effectiveness and Safety of 40 mg Modified-Release Doxycycline for the Treatment of Hidradenitis Suppurativa: A Single-Center Retrospective Observational Study.Dermatology and therapy · 2026Article
- AA amyloidosis with multiorgan involvement secondary to severe hidradenitis suppurativa: A case report.Medicine · 2026Article
- Real-world experience with upadacitinib in hidradenitis suppurativa: efficacy and safety in patients with dermatological comorbidities.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026Article
- Beyond Drainage: Clinical-Ultrasound Correlation Supports a Broader Definition of the Active Tunnel in Hidradenitis Suppurativa.Dermatology and therapy · 2026Article
- Patient Journey and Unmet Needs in Hidradenitis Suppurativa: Insights from an Italian Survey.Journal of clinical medicine · 2026Article
- Determinants of kinesiophobia in patients with hidradenitis suppurativa: the role of pain, fatigue, physical activity and depression.BMC psychology · 2026Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
37 authors.
Funding
Abstract
introductionThis second part of the S2k guidelines is an update of the 2015 S1 European guidelines.
objectiveThese guidelines aim to provide an accepted decision aid for the selection, implementation and assessment of appropriate and sufficient therapy for patients with hidradenitis suppurativa/acne inversa (HS).
methodsThe chapters have been selected after a Delphi procedure among the experts/authors. Certain passages have been adopted without changes from the previous version. Potential treatment complications are not included, being beyond the scope of these guidelines.
resultsSince the S1 guidelines publication, validation of new therapeutic approaches has almost completely overhauled the knowledge in the field of HS treatment. Inflammatory nodules/abscesses/draining tunnels are the primary lesions, which enable the classification of the disease severity by new validated tools. In relation to the degree of detectable inflammation, HS is classified into the inflammatory and the predominantly non-inflammatory forms. While the intensity of the inflammatory form can be subdivided by the IHS4 classification in mild, moderate and severe HS and is treated by medication accordingly, the decision on surgical treatment of the predominantly non-inflammatory form is based on the Hurley stage of the affected localization. The effectiveness of oral tetracyclines as an alternative to the oral combination of clindamycin/rifampicin should be noted. The duration of systemic antibiotic therapy can be shortened by a 5-day intravenous clindamycin treatment. Adalimumab, secukinumab and bimekizumab subcutaneous administration has been approved by the EMA for the treatment of moderate-to-severe HS. Various surgical procedures are available for the predominantly non-inflammatory form of the disease. The combination of a medical therapy to reduce inflammation with a surgical procedure to remove irreversible tissue damage is currently considered a holistic therapeutic approach.
conclusionsSuitable therapeutic options while considering HS severity in the therapeutic algorithm according to standardized criteria are aimed at ensuring a proper therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.